Med BioGene Inc.

Med BioGene Inc. (MBI) is a biotechnology company that is revolutionizing the diagnosis and treatment of certain cancers and cardiovascular disease by identifying the genes, known as "biomarkers," that indicate the presence of such diseases.

With a robust set of qualified biomarkers, disease diagnosis will be quicker, less invasive and more accurate. Moreover, treatment decisions will be tailored to the needs of each patient, the safety and effectiveness of new therapeutics will be enhanced and drug products will get to patients in less time.
The development of these biomarkers is the first step towards personalized medicine and will replace the conventional "one drug fits all" approach to disease management.

MBI is currently developing biomarkers for lymphoma and leukemia through its Hematological Cancer Profiling System™, and for cardiovascular disease through its Cardiovascular Disease Profiling System™.

T. Nathan Yoganathan, Ph.D.
Chairman, President and Chief Scientific Officer

T. Nathan Yoganathan, Ph.D. is the founder of MBI and has been President and Chief Scientific Officer since 2002. Dr. Yoganathan is an expert in gene expression technology and signalling pathways.

Dr. Yoganathan has over 18 years of experience in scientific research, with 15 years spent in biotechnology; and has published over 25 peer¬reviewed scientific papers. Dr. Yoganathan holds a B.Sc. (Honours) from the University of North London, an M.Sc. from the University of Sussex and a Ph.D. from the University of Oslo.

Dr. T. Nathan Yoganathan
President & CSO
Med BioGene Inc.
2386 East Mall
#300 -- Gerald McGavin Building
University of British Columbia Campus
Vancouver, BC V6T 1Z3
Phone: (604) 8274521
Mobile: 604 375 4519
Fax: (604) 827-5120
www.medbiogene.com